Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Keytruda | Pembrolizumab | Nonsquamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | MUC First line | Do not reimburse | Complete | ||
Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | recurrent, or metastatic cervical cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Classical Hodgkin lymphoma | Reimburse with clinical criteria and/or conditions | Complete |